Immuto Scientific and the University of Wisconsin announced recently a collaborative agreement to identify disease-specific novel therapeutic targets in colorectal cancer using Immuto’s proprietary structural surfaceomics platform.

“Our work with Dr. Deming and the University of Wisconsin-Madison represents an exceptional opportunity to study colorectal cancer in a clinically relevant form,” Immuto Scientific CEO and Co-Founder Faraz A. Choudhury, Ph.D., said in a statement. “By integrating patient-derived models with our structural surfaceomics platform, we can reveal previously unseen, disease-specific surface structures for drug targets that open new possibilities for therapeutic intervention.”

According to a release, Immuto will apply its high-resolution structural proteomics and AI-enabled analytics to interrogate conformational differences in cell-surface proteins between tumor and normal tissues.

The biotech company will receive access to uniquely characterized patient-derived organoid models representing microsatellite-stable colorectal cancer.

It is a multi-year collaboration.